Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27663410 | 0.86 | CXCR4 (0.47) | SMN1; SMN2POLBCXCR4ALDH1A1CHRM5 | |
| SCHEMBL20328760 | 0.82 | ALDH1A1 (0.41) | SMN1; SMN2POLBCXCR4ALDH1A1MAPT | |
| SCHEMBL12790350 | 0.80 | MEN1 (0.44) | MAPTSIGMAR1MEN1KMT2A | |
| SCHEMBL13397441 | 0.80 | MEN1 (0.44) | POLBSIGMAR1MEN1KMT2A | |
| SCHEMBL11813843 | 0.80 | CHRM5 (0.40) | SMN1; SMN2POLBCXCR4ALDH1A1MAPT | |
| SCHEMBL12790351 | 0.78 | MEN1 (0.42) | POLBALDH1A1MAPTSIGMAR1MEN1 | |
| SCHEMBL26350015 | 0.78 | CHRM5 (0.40) | SMN1; SMN2POLBCXCR4CHRM5CHRM3 | |
| SCHEMBL12359045 | 0.78 | MEN1 (0.37) | ALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL20328771 | 0.76 | CXCR4 (0.46) | SMN1; SMN2POLBCXCR4ALDH1A1MAPT | |
| SCHEMBL1363520 | 0.76 | CHRM5 (0.37) | SMN1; SMN2POLBCXCR4ALDH1A1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109575045-A | Thienopyrimidines, preparation method, Pharmaceutical composition and its application | 南京红云生物科技有限公司 | 2019-04-05 | — | — | CN | claimed |
| CN-109180677-A | Substituted aryl ethers compounds, preparation method, Pharmaceutical composition and its application | 厦门大学 | 2019-01-11 | — | — | CN | claimed |
| CN-103254944-B | A kind of method of Dresel fuel compositions and raising oxidation stability of biodiesel | SINOPEC CORP. (CN) | 2015-10-28 | — | — | CN | claimed |
| CN-103254945-B | A kind of method of Dresel fuel compositions and raising oxidation stability of biodiesel | SINOPEC CORP. (CN) | 2015-08-26 | — | — | CN | claimed |
| CN-103254951-B | Additive composition, diesel oil composition, and method for increasing oxidation stability of biodiesel | CHINA PETROLEUM & CHEMICAL | 2015-03-18 | — | — | CN | claimed |
| CN-103254950-B | Additive composition, diesel oil composition, and method for increasing oxidation stability of biodiesel | CHINA PETROLEUM & CHEMICAL | 2015-02-25 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-20100233264-A1 | TEMPERATURE AND pH-SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT SAFTY IN VIVO AND HYDROGEL AND DRUG DELIVERY SYSTEM USING THEREOF | SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) | 2010-09-16 | — | — | US | claimed |
| WO-2009031861-A2 | TEMPERATURE AND PH-SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT SAFETY IN VIVO AND HYDROGEL AND DRUG DELIVERY SYSTEM USING THEREOF | SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION (KR) | 2009-03-12 | — | — | WO | claimed |
| CN-116813493-A | Lipid compound, lipid carrier based on lipid compound, nucleic acid lipid nanoparticle composition and pharmaceutical preparation | 苏州科锐迈德生物医药科技有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023179497-A1 | LIPID COMPOUND, LIPID CARRIER BASED ON LIPID COMPOUND, NUCLEIC ACID LIPID NANOPARTICLE COMPOSITION AND PHARMACEUTICAL FORMULATION | 苏州科锐迈德生物医药科技有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-20220306603-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-09-29 | — | — | US | disclosed |
| US-20200368254-A1 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | TRUSTEES OF TUFTS COLLEGE | 2020-11-26 | — | — | US | disclosed |
| US-20190255009-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | OZCHELA INC (KR) | 2019-08-22 | — | — | US | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255009-A1 | STILBENE DERIVATIVE AND METHOD FOR PREPARING SAME | HPN, P4HB, FKBP1B | SMN1; SMN2 1141/4885POLB 2155/4885CXCR4 4606/4885 |
| US-20100233264-A1 | TEMPERATURE AND pH-SENSITIVE BLOCK COPOLYMER HAVING EXCELLENT SAFTY IN VIVO AND HYDROGEL AND DRUG DELIVERY SYSTEM USING THEREOF | CD44, PSAT1, ALAD | SMN1; SMN2 1925/4885POLB 1173/4885CXCR4 4385/4885 |
| US-20200368254-A1 | LIPID-LIKE NANOCOMPLEXES AND USES THEREOF | APOB, LDLR, LIPA | SMN1; SMN2 2996/4885POLB 397/4885CXCR4 934/4885 |
| US-20220306603-A1 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | ERCC4, ERCC1, ERCC2 | SMN1; SMN2 2606/4885POLB 815/4885CXCR4 2043/4885 |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | SMN1; SMN2 1061/4885POLB 430/4885CXCR4 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.